This week saw the publication of ELZA’s better pain management protocol in the Journal of Clinical Medicine, and represents a significant advance in the way pain
Newsflash: CXL reimbursed in Switzerland
Exactly 20 years after the clinical introduction of cross-linking and after more than 2,000 scientific publications on the subject, corneal cross-linking (CXL) for the treatment of progressive keratoconus has now been included in the Swiss healthcare reimbursement system (the “krankenkasse”).
In science, there is a mantra: “publish or perish”. However, there are almost 30,000 academic journals, and quantity does not equal quality. One of the
People with Down Syndrome have a disproportionately higher risk of developing keratoconus than the general population, and many go on to receive corneal cross-linking (CXL)
Journals place a lot of trust in their editorial board members: they set the focus and the tone of the journal, and as reviewers, they
Ophthalmology Times Europe interviewed the Medical Director of ELZA Institute, Prof. Farhad Hafezi, for this month’s cover feature story: An In-Depth Look at Corneal Ectasia.
Photoactivated chromophore for keratitis-corneal cross-linking (PACK-CXL) has progressed a great deal since it was first developed (1) as a treatment for infectious keratitis and corneal
Ophthalmology times asked Farhad Hafezi about what he thinks are the Ophthalmic Challenges in 2022
The ELZA Institute had a strong presence at the 82nd SBAO annual congress in Bern. Prof. Kaweh Mansouri, Dr. Emilio Torres-Netto and Ms. Julia Schinzel all
